TY - JOUR
T1 - Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
AU - Yachida, Shinichi
AU - Mizutani, Sayaka
AU - Shiroma, Hirotsugu
AU - Shiba, Satoshi
AU - Nakajima, Takeshi
AU - Sakamoto, Taku
AU - Watanabe, Hikaru
AU - Masuda, Keigo
AU - Nishimoto, Yuichiro
AU - Kubo, Masaru
AU - Hosoda, Fumie
AU - Rokutan, Hirofumi
AU - Matsumoto, Minori
AU - Takamaru, Hiroyuki
AU - Yamada, Masayoshi
AU - Matsuda, Takahisa
AU - Iwasaki, Motoki
AU - Yamaji, Taiki
AU - Yachida, Tatsuo
AU - Soga, Tomoyoshi
AU - Kurokawa, Ken
AU - Toyoda, Atsushi
AU - Ogura, Yoshitoshi
AU - Hayashi, Tetsuya
AU - Hatakeyama, Masanori
AU - Nakagama, Hitoshi
AU - Saito, Yutaka
AU - Fukuda, Shinji
AU - Shibata, Tatsuhiro
AU - Yamada, Takuji
N1 - Funding Information:
We thank all patients and their families who participated in this study, S. Goto for technical advice and A. Kaya, C. Shima, K. Igarashi, R. Usui, K. Murakami, I. Take, M. Sezawa, M. Iwahara, M. Komori, Z. Nakagawa, Y. Ohara and K. Kamezaki for expert technical assistance. Computations were partially performed on the NIG supercomputer at the ROIS National Institute of Genetics. This work was supported by grants from the National Cancer Center Research and Development Fund (25-A-4 and 28-A-4 to S.Y., S.F and T. Yamada and 29-A-6 to T. Yamada and T. Shibata); Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED) (JP18ek0109187 to S.Y., S.M., Y.S., S.F. and T. Yamada; JP18jk0210009 to S.Y. and T. Shibata); AMED-CREST (JP18gm0710003 to S.Y. and T. Soga.); JST (Japan Science and Technology Agency)-PRESTO (JPMJPR1537 to S.F. and JPMJPR1507 to T. Yamada); JSPS (Japan Society for the Promotion of Science) KAKENHI (16H04901, 17H05654 and 18H04805 to S.F.; 16J10135, 142558 and 221S0002 to T. Yamada); Joint Research Project of the Institute of Medical Science, the University of Tokyo (2017–2107 to S.Y. and T. Shibata); Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University (to S.Y.); the Takeda Science Foundation (to S.Y.) and Suzuken Memorial Foundation (H25–2–11 to S.Y.).
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - In most cases of sporadic colorectal cancers, tumorigenesis is a multistep process, involving genomic alterations in parallel with morphologic changes. In addition, accumulating evidence suggests that the human gut microbiome is linked to the development of colorectal cancer. Here we performed fecal metagenomic and metabolomic studies on samples from a large cohort of 616 participants who underwent colonoscopy to assess taxonomic and functional characteristics of gut microbiota and metabolites. Microbiome and metabolome shifts were apparent in cases of multiple polypoid adenomas and intramucosal carcinomas, in addition to more advanced lesions. We found two distinct patterns of microbiome elevations. First, the relative abundance of Fusobacterium nucleatum spp. was significantly (P < 0.005) elevated continuously from intramucosal carcinoma to more advanced stages. Second, Atopobium parvulum and Actinomyces odontolyticus, which co-occurred in intramucosal carcinomas, were significantly (P < 0.005) increased only in multiple polypoid adenomas and/or intramucosal carcinomas. Metabolome analyses showed that branched-chain amino acids and phenylalanine were significantly (P < 0.005) increased in intramucosal carcinomas and bile acids, including deoxycholate, were significantly (P < 0.005) elevated in multiple polypoid adenomas and/or intramucosal carcinomas. We identified metagenomic and metabolomic markers to discriminate cases of intramucosal carcinoma from the healthy controls. Our large-cohort multi-omics data indicate that shifts in the microbiome and metabolome occur from the very early stages of the development of colorectal cancer, which is of possible etiological and diagnostic importance.
AB - In most cases of sporadic colorectal cancers, tumorigenesis is a multistep process, involving genomic alterations in parallel with morphologic changes. In addition, accumulating evidence suggests that the human gut microbiome is linked to the development of colorectal cancer. Here we performed fecal metagenomic and metabolomic studies on samples from a large cohort of 616 participants who underwent colonoscopy to assess taxonomic and functional characteristics of gut microbiota and metabolites. Microbiome and metabolome shifts were apparent in cases of multiple polypoid adenomas and intramucosal carcinomas, in addition to more advanced lesions. We found two distinct patterns of microbiome elevations. First, the relative abundance of Fusobacterium nucleatum spp. was significantly (P < 0.005) elevated continuously from intramucosal carcinoma to more advanced stages. Second, Atopobium parvulum and Actinomyces odontolyticus, which co-occurred in intramucosal carcinomas, were significantly (P < 0.005) increased only in multiple polypoid adenomas and/or intramucosal carcinomas. Metabolome analyses showed that branched-chain amino acids and phenylalanine were significantly (P < 0.005) increased in intramucosal carcinomas and bile acids, including deoxycholate, were significantly (P < 0.005) elevated in multiple polypoid adenomas and/or intramucosal carcinomas. We identified metagenomic and metabolomic markers to discriminate cases of intramucosal carcinoma from the healthy controls. Our large-cohort multi-omics data indicate that shifts in the microbiome and metabolome occur from the very early stages of the development of colorectal cancer, which is of possible etiological and diagnostic importance.
UR - http://www.scopus.com/inward/record.url?scp=85067007334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067007334&partnerID=8YFLogxK
U2 - 10.1038/s41591-019-0458-7
DO - 10.1038/s41591-019-0458-7
M3 - Article
C2 - 31171880
AN - SCOPUS:85067007334
SN - 1078-8956
VL - 25
SP - 968
EP - 976
JO - Nature medicine
JF - Nature medicine
IS - 6
ER -